On July 1, 2025, 180 Life Sciences Corp. announced two significant value enhancements to its existing, legacy intellectual property (IP) portfolio. This reinforces a part of the company's strategy to build shareholder value through scientific innovation and patent protection.
These new developments reflect 180 Life Sciences' ongoing efforts to secure strong IP rights for its novel IP. The company is positioning these assets for potential future partnering, licensing, or strategic transactions.
This strategy is being pursued even as the company pivots its primary focus to the global iGaming sector. The aim is to maximize value for shareholders from its biotech assets while developing its new business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.